ClinicalTrials.gg
CompletedNCT03629054Updated Feb 21, 2020Results posted

This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills

A Phase 1 interventional study of Empagliflozin, Metformin HCl, Linagliptin (fixed dose combination) and Empagliflozin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-21.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary objective of this trial is to establish the bioequivalence of two empagliflozin/linagliptin/metformin extended release (XR) fixed dose combination (FDC) tablets (Test, T) compared with the same doses of the individual components given in separate tablets (Reference, R) when administered together after a high-fat, high-calorie meal.

The assessment of safety and tolerability will be the secondary objective of this trial.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects according to the assessment of the investigator, based on a complete medical history including a physical examination, vital signs (Blood pressure (BP), Pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 55 years (incl.)
  • (BMI) of 18.5 to 29.9 kg/m2 (incl.)
  • Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation
  • Female subjects of willing to use adequate .
  • Further inclusion criteria apply

Exclusion criteria

Exclusion criteria:

  • Any finding in the medical examination (including Blood pressure (BP), Pulse rate (PR) or (ECG)) is deviating from normal and judged as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm)
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • Further exclusion criteria apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Test treatment (T)

    Low strength empagliflozin/linagliptin/metformin XR fixed dose combination tablet

    Drug: Empagliflozin, Metformin HCl, Linagliptin (fixed dose combination)

  • Experimental
    Reference treatment (R)

    Single tablets of empagliflozin + linagliptin + metformin XR

    Drug: Empagliflozin · Drug: Linagliptin · Drug: Metformin HCl

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    AUC0-tz, Area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 to the last quantifiable data point is presented. Standard error (SE) is a geometric SE.

    Time frame: Pharmacokinetic (PK) samples were collected 1:30 hours:minutes (h:m) pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.

  2. Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    AUC0-tz, Area under the concentration-time curve of the metformin in plasma over the time interval from 0 to the last quantifiable data point is presented. Standard error (SE) is a geometric SE.

    Time frame: Pharmacokinetic (PK) samples were collected 1:30 hours:minutes (h:m) pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.

  3. Area Under the Concentration-time Curve of the Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (h) (AUC0-72)

    AUC0-72, area under the concentration-time curve of the linagliptin in plasma over the time interval from 0 to 72 h is presented. SE is a geometric SE.

    Time frame: PK samples were collected 1:30 h:m pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.

  4. Maximum Measured Concentration of the Empagliflozin in Plasma (Cmax)

    Cmax, maximum measured concentration of the empagliflozin in plasma is presented. SE is a geometric SE.

    Time frame: PK samples were collected 1:30 h:m pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.

  5. Maximum Measured Concentration of the Linagliptin in Plasma (Cmax)

    Cmax, maximum measured concentration of the linagliptin in plasma is presented. SE is a geometric SE.

    Time frame: PK samples were collected 1:30 h:m pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.

  6. Maximum Measured Concentration of the Metformin in Plasma (Cmax)

    Cmax, maximum measured concentration of the metformin in plasma is presented. SE is a geometric SE.

    Time frame: PK samples were collected 1:30 h:m pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.

Secondary outcomes

  1. Area Under the Concentration-time Curve of the Empagliflozin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    AUC0-∞, area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 extrapolated to infinity is presented. SE is a geometric SE.

    Time frame: PK samples were collected 1:30 h:m pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.

  2. Area Under the Concentration-time Curve of the Linagliptinin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    AUC0-∞, area under the concentration-time curve of the linagliptin in plasma over the time interval from 0 extrapolated to infinity is presented. SE is a geometric SE.

    Time frame: PK samples were collected 1:30 h:m pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.

  3. Area Under the Concentration-time Curve of the Metformin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    AUC0-∞, area under the concentration-time curve of the metformin in plasma over the time interval from 0 extrapolated to infinity is presented. SE is a geometric SE.

    Time frame: PK samples were collected 1:30 h:m pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.

  4. Percentage of Patients With Drug-related Adverse Events (AEs)

    Percentage of patients with investigator defined drug-related AEs are presented.

    Time frame: All adverse events (AEs) which occurred through the treatment phase and throughout the residual effect period (REP), up to 7 days.

07

Results

Posted Feb 21, 2020

Participant flow

It was planned to include healthy participants in this randomised, open-label, two-way crossover trial with 2 treatments (test treatment (T) and reference treatment (R)) and 2 treatment sequences (TR or RT) in order to compare the treatment T to the treatment R under fed conditions. They were recruited from the volunteers' pool of the study site.

Period 1 (4 Days)
Participant flow — Period 1 (4 Days)
MilestoneTest Treatment (T)/ Reference Treatment (R)Reference Treatment (R)/ Test Treatment (T)
Started1515
Completed1515
Not completed00
Wasout Period (35 Days)
Participant flow — Wasout Period (35 Days)
MilestoneTest Treatment (T)/ Reference Treatment (R)Reference Treatment (R)/ Test Treatment (T)
Started1515
Completed1515
Not completed00
Period 2 (4 Days)
Participant flow — Period 2 (4 Days)
MilestoneTest Treatment (T)/ Reference Treatment (R)Reference Treatment (R)/ Test Treatment (T)
Started1515
Treated1514
Completed1514
Not completed01
Withdrew: Not treated01

Outcome measures

PrimaryArea Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

AUC0-tz, Area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 to the last quantifiable data point is presented. Standard error (SE) is a geometric SE.

Time frame:
Pharmacokinetic (PK) samples were collected 1:30 hours:minutes (h:m) pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.
Reported as:
Geometric mean · nanomole*hour/litre (nmol*h/L)
Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
nanomole*hour/litre (nmol*h/L)Test Treatment (T)Reference Treatment (R)
Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)2134.53 ± 1.032125.57 ± 1.03
Statistical analysis
  • Test Treatment (T) vs Reference Treatment (R) · ANOVA · p = <0.0001 · Adjusted gmean ratio: 100.42 · 90% CI 98.17 to 102.72gMean ratio = T/R. Standard error of the mean is actually intra-individual geometric coefficient of variation (gCV).
PrimaryArea Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

AUC0-tz, Area under the concentration-time curve of the metformin in plasma over the time interval from 0 to the last quantifiable data point is presented. Standard error (SE) is a geometric SE.

Time frame:
Pharmacokinetic (PK) samples were collected 1:30 hours:minutes (h:m) pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.
Reported as:
Geometric mean · nanogram*h/mL (ng*h/mL)
Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
nanogram*h/mL (ng*h/mL)Test Treatment (T)Reference Treatment (R)
Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)21687.12 ± 1.0422748.21 ± 1.04
Statistical analysis
  • Test Treatment (T) vs Reference Treatment (R) · ANOVA · p = <0.0001 · Adjusted gmean ratio: 95.34 · 90% CI 91.58 to 99.24gMean ratio = T/R. Standard Error of the mean is actually intra-individual gCV.
PrimaryArea Under the Concentration-time Curve of the Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (h) (AUC0-72)

AUC0-72, area under the concentration-time curve of the linagliptin in plasma over the time interval from 0 to 72 h is presented. SE is a geometric SE.

Time frame:
PK samples were collected 1:30 h:m pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.
Reported as:
Geometric mean · nmol*h/L
Area Under the Concentration-time Curve of the Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (h) (AUC0-72)
nmol*h/LTest Treatment (T)Reference Treatment (R)
Area Under the Concentration-time Curve of the Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (h) (AUC0-72)270.19 ± 1.03269.77 ± 1.03
Statistical analysis
  • Test Treatment (T) vs Reference Treatment (R) · ANOVA · p = <0.0001 · Adjusted gmean ratio: 100.16 · 90% CI 96.17 to 104.31gMean ratio = T/R. Standard Error of the mean is actually intra-individual gCV.
PrimaryMaximum Measured Concentration of the Empagliflozin in Plasma (Cmax)

Cmax, maximum measured concentration of the empagliflozin in plasma is presented. SE is a geometric SE.

Time frame:
PK samples were collected 1:30 h:m pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.
Reported as:
Geometric mean · nanomole/Litre (nmol/ L)
Maximum Measured Concentration of the Empagliflozin in Plasma (Cmax)
nanomole/Litre (nmol/ L)Test Treatment (T)Reference Treatment (R)
Maximum Measured Concentration of the Empagliflozin in Plasma (Cmax)209.67 ± 1.05226.50 ± 1.05
Statistical analysis
  • Test Treatment (T) vs Reference Treatment (R) · ANOVA · p = 0.0029 · Adjusted gmean ratio: 92.57 · 90% CI 85.21 to 100.57gMean ratio = T/R. Standard Error of the mean is actually intra-individual gCV.
PrimaryMaximum Measured Concentration of the Linagliptin in Plasma (Cmax)

Cmax, maximum measured concentration of the linagliptin in plasma is presented. SE is a geometric SE.

Time frame:
PK samples were collected 1:30 h:m pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.
Reported as:
Geometric mean · nanomole/Litre (nmol/ L)
Maximum Measured Concentration of the Linagliptin in Plasma (Cmax)
nanomole/Litre (nmol/ L)Test Treatment (T)Reference Treatment (R)
Maximum Measured Concentration of the Linagliptin in Plasma (Cmax)7.02 ± 1.057.21 ± 1.05
Statistical analysis
  • Test Treatment (T) vs Reference Treatment (R) · ANOVA · p = 0.0001 · Adjusted gmean ratio: 97.33 · 90% CI 89.99 to 105.26gMean ratio = T/R. Standard Error of the mean is actually intra-individual gCV.
PrimaryMaximum Measured Concentration of the Metformin in Plasma (Cmax)

Cmax, maximum measured concentration of the metformin in plasma is presented. SE is a geometric SE.

Time frame:
PK samples were collected 1:30 h:m pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.
Reported as:
Geometric mean · nanogram/ millilitre (ng/ mL)
Maximum Measured Concentration of the Metformin in Plasma (Cmax)
nanogram/ millilitre (ng/ mL)Test Treatment (T)Reference Treatment (R)
Maximum Measured Concentration of the Metformin in Plasma (Cmax)1853.03 ± 1.041767.69 ± 1.04
Statistical analysis
  • Test Treatment (T) vs Reference Treatment (R) · ANOVA · p = <0.0001 · Adjusted gmean ratio: 104.83 · 90% CI 98.56 to 111.50gMean ratio = T/R. Standard Error of the mean is actually intra-individual gCV.
SecondaryArea Under the Concentration-time Curve of the Empagliflozin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

AUC0-∞, area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 extrapolated to infinity is presented. SE is a geometric SE.

Time frame:
PK samples were collected 1:30 h:m pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.
Reported as:
Geometric mean · nmol*h/L
Area Under the Concentration-time Curve of the Empagliflozin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
nmol*h/LTest Treatment (T)Reference Treatment (R)
Area Under the Concentration-time Curve of the Empagliflozin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)2182.26 ± 1.032166.54 ± 1.03
Statistical analysis
  • Test Treatment (T) vs Reference Treatment (R) · ANOVA · p = <0.0001 · Adjusted gmean ratio: 100.73 · 90% CI 98.33 to 103.18gMean ratio = T/R. Standard Error of the mean is actually intra-individual gCV.
SecondaryArea Under the Concentration-time Curve of the Linagliptinin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

AUC0-∞, area under the concentration-time curve of the linagliptin in plasma over the time interval from 0 extrapolated to infinity is presented. SE is a geometric SE.

Time frame:
PK samples were collected 1:30 h:m pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.
Reported as:
Geometric mean · nmol*h/L
Area Under the Concentration-time Curve of the Linagliptinin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
nmol*h/LTest Treatment (T)Reference Treatment (R)
Area Under the Concentration-time Curve of the Linagliptinin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)471.40 ± 1.05455.13 ± 1.05
Statistical analysis
  • Test Treatment (T) vs Reference Treatment (R) · ANOVA · p = <0.0001 · Adjusted gmean ratio: 103.57 · 90% CI 96.90 to 110.71gMean ratio = T/R. Standard Error of the mean is actually intra-individual gCV.
SecondaryArea Under the Concentration-time Curve of the Metformin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

AUC0-∞, area under the concentration-time curve of the metformin in plasma over the time interval from 0 extrapolated to infinity is presented. SE is a geometric SE.

Time frame:
PK samples were collected 1:30 h:m pre-dose and 0:30, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 34:00, 48:00 and 72:00 h:m after drug administration.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-time Curve of the Metformin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
ng*h/mLTest Treatment (T)Reference Treatment (R)
Area Under the Concentration-time Curve of the Metformin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)22288.72 ± 1.0423280.48 ± 1.04
Statistical analysis
  • Test Treatment (T) vs Reference Treatment (R) · ANOVA · p = <0.0001 · Adjusted gmean ratio: 95.74 · 90% CI 92.29 to 99.32gMean ratio = T/R. Standard Error of the mean is actually intra-individual gCV.
SecondaryPercentage of Patients With Drug-related Adverse Events (AEs)

Percentage of patients with investigator defined drug-related AEs are presented.

Time frame:
All adverse events (AEs) which occurred through the treatment phase and throughout the residual effect period (REP), up to 7 days.
Reported as:
Number · Participants
Percentage of Patients With Drug-related Adverse Events (AEs)
ParticipantsTest Treatment (T)Reference Treatment (R)
Percentage of Patients With Drug-related Adverse Events (AEs)76

Adverse events

Collected over All adverse events (AEs) which occurred through the treatment phase and throughout the residual effect period (REP), up to 7 days. All cause mortality and serious AEs are considering the entire duration of the trial, 49 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Treatment (T)0/29 (0%)0/29 (0%)8/29 (27.6%)
Reference Treatment (R)0/30 (0%)0/30 (0%)6/30 (20%)
Most frequent other events
Most frequent other events
EventTest Treatment (T)Reference Treatment (R)
NauseaGastrointestinal disorders4/293/30
HeadacheNervous system disorders4/292/30
NasopharyngitisInfections and infestations2/291/30
Decreased appetiteMetabolism and nutrition disorders1/292/30

Baseline characteristics

The treated set (TS): TS included all subjects who were documented to have received at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)Test Treatment (T)/ Reference Treatment (R)Reference Treatment (R)/ Test Treatment (T)Total
Mean46.9 ± 7.641.5 ± 9.744.2 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Test Treatment (T)/ Reference Treatment (R)Reference Treatment (R)/ Test Treatment (T)Total
Female6511
Male91019
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Test Treatment (T)/ Reference Treatment (R)Reference Treatment (R)/ Test Treatment (T)Total
Hispanic or Latino000
Not Hispanic or Latino151530
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Test Treatment (T)/ Reference Treatment (R)Reference Treatment (R)/ Test Treatment (T)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White151429
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). Requestors can use the following link http:// trials.boehringer-ingelheim.com/ to: find information in order to request access to clinical study data, for listed studies. request access to clinical study documents that meet criteria, and upon a signed 'Document Sharing Agreement'.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Nov 2018, 2 months.

Results were first posted in Feb 2020, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2018
First posted
Aug 14, 2018
StartActual
Aug 27, 2018
Primary completionActual
Nov 5, 2018
CompletionActual
Nov 5, 2018
Results first posted
Feb 21, 2020
Last update
Feb 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03629054
Responsible party
Sponsor
First posted
Aug 14, 2018
Start date
Aug 27, 2018
Primary completion
Nov 5, 2018
Completion
Nov 5, 2018
Results posted
Feb 21, 2020
Last update
Feb 21, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Metformin · Linagliptin

Start the discussion